Clinical uses of metal-binding drugs.
D000136:Acid-Base Equilibrium / Q000187:drug effects; D000284:Administration, Oral; D020261:Arsenic Poisoning; D002128:Calcium Metabolism Disorders / Q000188:drug therapy; D002614:Chelating Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004112:Dimercaprol / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D004339:Drug Compounding; D004358:Drug Therapy; D004492:Edetic Acid / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006527:Hepatolenticular Degeneration / Q000188:drug therapy; D006801:Humans; D007275:Injections, Intravenous; D007501:Iron / Q000506:poisoning; D007503:Iron Isotopes; D007855:Lead Poisoning / Q000188:drug therapy; D008297:Male; D008630:Mercury Poisoning / Q000188:drug therapy; D009824:Ointments; D010396:Penicillamine / Q000494:pharmacology* / Q000627:therapeutic use; D004369:Pentetic Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D011005:Plutonium / Q000009:adverse effects; D011041:Poisoning / Q000188:drug therapy; D011877:Radionuclide Imaging; D013607:Tablets
D002614:Chelating Agents; D007503:Iron Isotopes; D009824:Ointments; D013607:Tablets; D004112:Dimercaprol; D011005:Plutonium; D004369:Pentetic Acid; D004492:Edetic Acid; D007501:Iron; D010396:Penicillamine; D003676:Deferoxamine